Please assess the completion status of the following clinical trial:

Trial Title: MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic multiple myeloma, ISS stage 1, 2 or 3 within 12 months of starting therapy.~2. Completion of induction therapy with VGPR, or better, by IMWG criteria. All induction myeloma therapy (oral or intravenous, including steroids) must have been discontinued for 3 weeks prior to the first immunization. Subjects did not need to have measurable disease at the time of the screening visit.~3. Signed separate informed consent for stem cell mobilization and high-dose chemotherapy/auto-SCT, and was found to be eligible for SCT by standard institutional criteria.~4. MAGE-A3 expression determined by immunohistochemistry (IHC) present in a bone marrow specimen or plasmacytoma specimen.~5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.~6. The following laboratory parameters within the ranges specified:~   * Neutrophil count: ≥ 1.5 x 109/L~  * Lymphocyte count: ≥ 0.5 x 109/L~  * Platelet count: ≥ 50 x 109/L~  * Serum creatinine: ≤ 2 mg/dL~  * Serum bilirubin: \< 1.5 x the upper limit of normal (ULN)~  * Aspartate and alanine aminotransferase (AST and ALT): \< 2 x ULN~  * Hemoglobin: ≥ 8.0 g/dL~  * International normalized ratio (INR): ≤ 1.5~  * Partial thromboplastin time: ≤ 1.5 x ULN (unless known history of anti-phospholipid antibody or lupus anticoagulant)~7. Age ≥ 18 years.~8. Able and willing to give valid written informed consent.~Exclusion Criteria:~1. Prior treatment with melphalan (Alkeran®), other than 1 cycle (4 days) of oral melphalan.~2. Prior autologous or allogeneic SCT.~3. Prior immunization against MAGE-A3 or other cancer-testis antigens.~4. Concurrent malignancies, except for treated non-melanoma skin cancer and cervical carcinoma in situ.~5. Known immunodeficiency, human immunodeficiency virus (HIV) positivity, or active hepatitis B or C.~6. Known allergy or history of life-threatening reaction to G-CSF or GM-CSF.~7. History of autoimmune disease (eg., rheumatoid arthritis, lupus), other than vitiligo, diabetes, or treated thyroiditis.~8. History of severe allergic reactions to vaccines or unknown allergens.~9. History of myocardial infarction, angina, congestive heart failure, ventricular tachyarrhythmia, stroke or transient ischemic attack within the previous 6 months.~10. Other serious illnesses or co-morbid conditions (e.g., serious infections requiring antibiotics, bleeding disorders, other heart or lung conditions) that, in the opinion of the investigator, made the subject inappropriate for high-dose melphalan and auto-SCT.~11. Pregnancy and breastfeeding.~12. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization.~13. Mental impairment that may have compromised the ability to give informed consent and comply with the requirements of the study.~14. Lack of availability for immunological and clinical follow-up assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- recMAGE-A3 Protein + AS15 Adjuvant (Type: EXPERIMENTAL): Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete